Amivantamab是一款人源化EGFR/MET双特异性抗体。它具有多重抗癌的作用机制，不但能够阻断EGFR和MET介导的信号传导，还可以引导免疫细胞靶向携带激活性和耐药性EGFR/MET突变和扩增的肿瘤。The press release pointed out that compared to chemotherapy alone, the combination therapy of amivantamab and chemotherapy is the first treatment option to significantly improve the progression-free survival (PFS) in this patient population.
According to Cnstock, Johnson & Johnson (JNJ.US) announced that the European Commission (EC) has approved its bispecific antibody Rybrevant (amivantamab) for use in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) carrying exon 19 deletion (ex19del) or exon 21 L858R substitution mutations of the epidermal growth factor receptor (EGFR), who have previously received treatment including EGFR tyrosine kinase inhibitors (TKIs) and experienced disease progression. The press release pointed out that compared to chemotherapy alone, the combination therapy of amivantamab and chemotherapy is the first treatment option to significantly improve the progression-free survival (PFS) in this patient population.
The data from MARIPOSA-2 also showed for the first time that the amivantamab combination therapy can provide intracranial activity. Specifically, compared to patients receiving chemotherapy alone, the combination therapy with amivantamab reduced the risk of intracranial progression or death by 45%, with a median intracranial progression-free survival of 12.5 months and 8.3 months, respectively (HR=0.55; 95% CI: 0.38-0.79; P=0.001). According to the press release, due to the possibility of brain metastases in nearly 30% of patients with this type of disease, this finding is crucial for the patients.
Amivantamab is a human EGFR/MET bispecific antibody. It has multiple mechanisms of anticancer action, not only blocking the signaling mediated by EGFR and MET, but also guiding immune cells to target tumors carrying activated and resistant EGFR/MET mutations and amplifications.